NCT07521137尚未招募2 期
A Randomized, Double-Blind, Placebo-Controlled Phase 2a Study Evaluating the Safety, Tolerability, and Efficacy of OCF001 Intravaginal Gel in Women With Acute Vulvovaginal Candidiasis
Sano Chemicals Inc1 个研究点 分布在 1 个国家目标入组 36 人开始时间: 2026年4月20日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 36
- 试验地点
- 1
- 主要终点
- To evaluate the clinical cure of OCF001 (drug product) to treat acute VVC infection following 7-day intravaginal dose of drug product
研究概览
简要总结
A Randomized, Double-Blind, Placebo-Controlled Phase 2a Study Evaluating the Safety, Tolerability, and Efficacy of OCF001 Intravaginal Gel in Women with Acute Vulvovaginal Candidiasis
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Female participants, 18-65 years of age, inclusive.
- •Clinical diagnosis of symptomatic VVC or RVVC confirmed at baseline by positive KOH wet mount (i.e., when examined microscopically, vaginal secretions obtained by swab of the vaginal mucosa, placed on a slide and diluted with 10% room temperature potassium hydroxide (KOH) reveal filamentous hyphae/pseudohyphae and/or budding yeast cells).
- •VSS ≥ 5 with ≥2 signs
- •KOH or wet prep ≥ budding yeast or pseudohyphae
- •Vaginal pH ≤ 4.5
- •Positive culture for Candida at baseline
- •Presence of at least one vulvovaginal sign (vulvovaginal erythema, edema, or excoriation) as assessed by the investigator at baseline.
- •Presence of at least one vulvovaginal symptom (vulvovaginal itching, burning, or irritation) as reported by the subject at baseline.
- •Have a body weight range of ≥45kg/99 lbs to ≤110 kg/242 lbs and a body mass index (BMI) of 18-35 kg/m
- •Participant is not menstruating at Screening or Day 1 and, based on her menstrual cycle history, is not expected to menstruate during the 7-day intravaginal dosing period.
- •In good general health with no clinically relevant abnormalities based on the medical history, vital signs, physical examination, clinical laboratory evaluations (hematology and clinical chemistry), and 12-lead electrocardiogram (ECG) that, in the opinion of the investigator and sponsor, would affect participant's safety.
- •Participants who are not surgically sterile must use a medically accepted contraceptive regimen for at least 60 days before the baseline visit and agree to continue such use throughout the duration of the study. Reliable forms of contraception include intrauterine devices in place for at least 3 months, oral hormonal contraceptives, and abstinence. Women of childbearing potential must have a negative serum pregnancy test (beta-HCG) at screening and Day
- •Participants must be non-lactating.
- •Able to provide written informed consent.
- •Able to comply with all protocol-specified assessments and the study visit schedule.
排除标准
- •Clinically significant cardiovascular, hematological, renal, hepatic, pulmonary, endocrine, gastrointestinal, immunological, dermatological, neurological, or psychiatric disease.
- •Clinically significant illness or clinically significant surgery within 4 weeks before the administration of study medication.
- •Positive screen for hepatitis B surface antigen (HBsAg), hepatitis C antibody, or human immunodeficiency virus (HIV) antibody.
- •Allergy to any of the components of OCF001 or similar compounds.
- •Women not consenting for sexual abstinence from day 1 to day 10 and on days of drug product administration.
- •Pregnant or breastfeeding women excluded
- •Positive pregnancy test at screening excludes
- •Receipt of an investigational product or device, or participation in a drug research study within a period of 30 days (or 5 half-lives of the drug, whichever is longer) before baseline.
- •Prescription medications that have not been taken on a stable dosing regimen for at least 30 days.
- •Participants must not use any systemic (e.g., oral or injectable) corticosteroid therapy during the study or within 30 days prior to Screening. However, use of topical (no vulvar or vaginal steroids), inhaled, ophthalmic, intraarticular and intralesional steroids is permitted.
- •Participants must not have received an immunosuppressive medication (e.g. cyclosporine, tacrolimus, methotrexate, etc.), or radiation therapy within 3 months prior to Screening or have a medical condition where it would be likely that the participant may need to use these therapies during the study.
- •Use of any intravaginal prescription medication or over-the-counter products within 14 days before administration of study medication.
- •Presence of any significant vulvar or vaginal lesions.
- •Presence of a vaginal discharge consistent with Chlamydia, Trichomonas or bacterial vaginosis. Mixed infections of fungi and parasitic/bacterial origin.
- •Findings of an abnormal PAP smear (ASCUS allowable), abnormal vaginal pH or positive Chlamydia/Gonorrhea testing.
- •Presence of inguinal adenopathy.
- •Donation of blood over 500 mL within three months prior to Screening.
- •Participants must not be using drugs with a narrow therapeutic index that are metabolized by CYP3A4 and sensitive to induction or inhibition of CYP3A4, CYP2C9 and CYP2C19 during the study.
- •Serum alanine aminotransferase (ALT), serum aspartate aminotransferase (AST) >2.5x the upper limit of normal (ULN) of the reference range.
- •Serum creatinine elevation > 2.0 mg/dL
- •Serum total bilirubin >1.5x the ULN of the reference range, unless the elevation is consistent with Gilbert's Syndrome.
- •QTcF interval≥500 ms as corrected by the Fridericia formula or QTcF interval change from baseline >60 ms, or any clinically significant electrocardiographic abnormality.
研究组 & 干预措施
Occidiofungin
Experimental
Participants will receive 5 g of OCF001 vaginal gel once daily for 7 days.
干预措施: OCF001 Intravaginal Gel (Drug)
Placebo
Placebo Comparator
Participants will receive 5 g of placebo vaginal gel once daily for 7 days
干预措施: Placebo Gel (Drug)
结局指标
主要结局
To evaluate the clinical cure of OCF001 (drug product) to treat acute VVC infection following 7-day intravaginal dose of drug product
时间窗: 7 days
Proportion of subjects achieving clinical cure at the Early Response, Test-of-Cure (TOC), and Sustained Response visits (Days 4, 8, and 25), defined as a VSS composite score, VSS total score = 0, and no requirement for additional systemic or topical antifungal therapy for VVC between baseline and TOC.
Evaluate the safety and local tolerability of OCF001 (drug product) intravaginal formulation in women with moderate-to-severe acute VVC.
时间窗: 4 weeks
Incidence, severity, and relationship to study drug of treatment-emergent adverse events (TEAEs) from first dose through the end-of-study visits (including local vulvovaginal AEs).
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
招募中
2 期
Study to Assess Efficacy and Safety of HSK39297 Tablets in Patients With LNNCT07363460Haisco Pharmaceutical Group Co., Ltd.105
招募中
1 期
A First-in-Human Single and Multiple Ascending Dose Study of MT-251NCT07423299Mirador Therapeutics, Inc.70
招募中
1 期
A Study of SKB575 (HBM7575) Injection in Healthy Participants and Atopic Dermatitis ParticipantsAtopic DermatitisNCT07488065Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.90
已完成
1 期
Phase I Study of PollenVax in Patients With Mugwort Pollen-Induced Allergic RhinitisRhinitis AllergicNCT07317960Kazakh National Agrarian University30
进行中（未招募）
2 期
A Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in Participants With Type 2 Diabetes MellitusNCT07321678Ascletis Pharma (China) Co., Limited100